Sun Pharma and Philogen Sign Exclusive Deal to Commercialize Anti-Cancer Drug Fibromun

Oct 1, 2024, 08:52 AM

Sun Pharma has entered into an exclusive global commercialization, licensing, and supply agreement with Swiss-Italian company Philogen to commercialize Fibromun, a specialty cancer anti-cancer immunotherapy drug. This partnership aims to leverage Sun Pharma's extensive market reach to bring Fibromun to a broader range of patients worldwide.